Trials / Unknown
UnknownNCT06158945
The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Sohag University · Academic / Other
- Sex
- All
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Accepted
Summary
Sickle cell disease (SCD) refers to a group of hemoglobinopathies that include mutations in the gene encoding the beta subunit of hemoglobin. Within the umbrella of SCD, many subgroups exist, namely sickle cell anemia (SCA), hemoglobin SC disease (HbSC), and hemoglobin sickle-beta-thalassemia (beta-thalassemia positive or beta-thalassemia negative). Several other minor variants within the group of SCDs also, albeit not as common as the varieties mentioned above. It is essential to mention the sickle cell trait (HbAS), which carries a heterozygous mutation and seldom presents clinical signs or symptoms. Sickle cell anemia is the most common form of SCD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | urinary endothelin 1 | assesment of endothelin 1 in urinary sample |
Timeline
- Start date
- 2023-10-24
- Primary completion
- 2024-10-23
- Completion
- 2024-10-23
- First posted
- 2023-12-06
- Last updated
- 2023-12-06
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06158945. Inclusion in this directory is not an endorsement.